Sepsis and Septic Shock

Sebastiano Leone


UOC Malattie Infettive AO San Giuseppe Moscati, Avellino sebastianoleone@yahoo.it

Sepsis and Septic Shock (point of view of infectious diseases specialist)

Sebastiano Leone


UOC Malattie Infettive AO San Giuseppe Moscati, Avellino sebastianoleone@yahoo.it

Global sepsis incidence



https://vizhub.healthdata.org/microbe/ Rudd KE, Lancet. 2020 Jan 18;395(10219):200-211.

Global sepsis mortality



Road map


- Time-to-antibiotics and clinical outcomes
- Initial treatment for MRSA infections
- Role of piperacillin/tazobactam in CRO-R *E. coli* infections
- Carbapenemase-producing *Enterobacterales* BSI in rectal carriers
- Impact on clinical outcome of follow-up blood cultures
- Early oral switch in bloodstream infections

Road map

• Time-to-antibiotics and clinical outcomes

- Initial treatment for MRSA infections
- Role of piperacillin/tazobactam in CRO-R *E. coli* infections
- Carbapenemase-producing *Enterobacterales* BSI in rectal carriers
- Impact on clinical outcome of follow-up blood cultures
- Early oral switch in bloodstream infections

Microbiological model of sepsis: role of antimicrobial therapy



Hour-1 Bundle - Initial Resuscitation for Sepsis and Septic Shock Surviving Sepsis Campaign 2021

Measure lactate level	remeasure lactate if initial lactate elevated (>2 mmol/L)
Obtain blood cultures	obtain blood cultures before administering antibiotics
Antibiotic therapy	administer broad-spectrum antibiotics
Fluid resuscitation	begin rapid administration of 30 mL/kg crystalloid for hypotension or lactate $\geq\!\!4$ mmol/L
Vasopressor therapy	vasopressors if hypotensive after fluid resuscitation to maintain a mean arterial pressure ≥65 mm Hg

Time-to-antibiotics and clinical outcomes in patients with sepsis and septic shock

This study analyzed prospectively collected data from an ongoing multicenter cohort of patients with sepsis identified in the emergency department. Adjusted ORs were compared for inhospital mortality of patients who had received antibiotics within 1 h to that of those who did not.


Overall, 3035 patients were included in the analysis. Among them, 601 (19.8%) presented with septic shock, and 774 (25.5%) died. Risk-adjusted ORs for in-hospital mortality associated with administration of broad-spectrum antibiotics in 1 h

In-hospital mortality	Adminis spectru	<i>p</i> -value	
	No	Yes OR (95% CI)*	

All participants (n = 3035)

	Overall	Reference	0.78 (0.61–0.99)	0.046
	Without septic shock	Reference	0.85 (0.64–1.15)	0.300
	With septic shock	Reference	0.66 (0.44–0.99)	0.049
*La	ndmark analysis (N = 301	8)		
	Overall	Reference	0.78 (0.61–0.99)	0.046
	Without septic shock	Reference	0.86 (0.64–1.15)	0.310
	With septic shock	Reference	0.65 (0.43–0.98)	0.042

Estimated ORs for in-hospital mortality by time-to-antibiotics, confined to patients with time-to-antibiotics within 3h



Within 3 h, patients without septic shock no showed (OR 1.01; 95%CI 0.82-1.23) increased risk of mortality by every 1h delay in antibiotic administration

Within 3 h, patients with septic shock showed 35% (OR 1.35; 95%CI 1.01-1.812) increased risk of mortality by every 1h delay in antibiotic administration

Association between time to appropriate antimicrobial treatment and 30-day mortality in patients with bloodstream infections


Retrospective cohort study (Sweden). Adult patients admitted between the years 2012 and 2019, with onset of BSI at the emergency department or general wards, were included (10628 BSI-episodes). Overall, 30-day mortality was 11.8%.

Landmark time	Inappropriate therapy	Appropriate therapy		Risk of mortality
	Events (Episodes)	Events (Episodes)		Adjusted odds ratio (95% CI)
Total cohort				
1 hour	750 (7022)	447 (3266)	⊢●⊣	0.83 (.7295)
3 hours	530 (4699)	631 (5346)	⊢● →	1.00 (.87 - 1.15)
6 hours	392 (3404)	730 (6458)	⊢ ∎1	1.05 (.91 - 1.22)
12 hours	323 (2594)	752 (7129)	⊢● –1	1.17 (1.01 - 1.37)
24 hours	227 (1755)	776 (7837)	⊢ ●−−1	1.24 (1.04 - 1.47)
48 hours	150 (1092)	784 (8461)	⊢	1.41 (1.15 - 1.74)
72 hours	99 (657)	768 (8908)	·	1.67 (1.30 - 2.15)

Delays in appropriate antimicrobial treatment were associated with increased 30-day mortality after 12 hours from blood culture collection, but not at 1, 3, and 6 hours, in BSI.


Heterogeneity of benefit from earlier time-to-antibiotics for sepsis

Observational cohort study of patients hospitalized with community-onset sepsis at 173 hospitals and treated with antimicrobials within 12 hours. Among 273.255 patients with community-onset sepsis, 131.094 (48.0%) received antibiotics within 3 hours.



Absolute risk of 30-day mortality according to patient characteristics

Observational cohort study of patients hospitalized with community-onset sepsis at 173 hospitals and treated with antimicrobials within 12 hours. Among 273,255 patients with community-onset sepsis, 131,094 (48.0%) received antibiotics within 3 hours.



Road map

- Time-to-antibiotics and clinical outcomes
- Initial treatment for MRSA infections
- Role of piperacillin/tazobactam in CRO-R *E. coli* infections
- Carbapenemase-producing *Enterobacterales* BSI in rectal carriers
- Impact on clinical outcome of follow-up blood cultures
- Early oral switch in bloodstream infections

Efficacy and safety of vancomycin for the treatment of *S. aureus* bacteraemia: a systematic review and meta-analysis

Microbiological response 15 controlled studies, including 1027 patients


Clinical response 15 controlled studies, including 1545 patients

	Vancom	ycin	Compara	ators		Odds Ratio	Odds Ratio		Vancom	ycin	Compara	ators		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% CI	Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
1991 Auwera (TEC)	3	7	3	4	2.4%	0.25 [0.02, 3.77]		1991 Auwera (TEC)	3	7	2	4	0.8%	0.75 [0.06, 8.83]	
1991 Gilbert (TEC)	6	8	9	15	1.7%	2.00 [0.30, 13.44]		1991 Gilbert (TEC)	6	8	9	15	0.8%	2.00 [0.30, 13.44]	
1994 Rolston (TEC)	5	6	5	5	1.4%	0.33 [0.01, 10.11]		1994 Menichetti (TEC)	11	13	14	15	1.1%	0.39 [0.03, 4.92]	
1996 Liu (TEC)	15	20	17	20	4.7%	0.53 [0.11, 2.60]		1996 Liu (TEC)	7	20	7	20	2.5%	1.00 [0.27, 3.67]	
2003 Jantausch (LNZ)	3	4	2	3	0.6%	1.50 [0.06, 40.63]		1999 Raad (QD)	1	2	3	7	0.4%	1.33 [0.06, 31.12]	· · · · · · · · · · · · · · · · · · ·
2004 D'Antonio (TEC)	8	10	4	6	1.1%	2.00 [0.20, 19.91]		2002 Stevens (LNZ)	15	32	17	33	4.8%	0.83 [0.31, 2.20]	
2012 Cheng (DAP)	41	52	22	26	6.9%	0.68 [0.19, 2.38]		2008 Kim (β-Lactam)	16	27	200	267	8.1%	0.49 [0.22, 1.10]	
2012 Moore (DAP)	107	118	53	59	7.3%	1.10 [0.39, 3.14]		2012 Moore (DAP)	81	118	49	59	11.0%	0.45 [0.20, 0.98]	
2013 Murray (DAP)	49	85	69	85	32.4%	0.32 [0.16, 0.63]		2013 Murray (DAP)	44	85	68	85	17.7%	0.27 [0.14, 0.53]	
2014 Stryjewski (ASP/TLV)	5	6	9	11	1.2%	1.11 [0.08, 15.53]		2014 Stryjewski (ASP/TLV)	6	6	9	11	0.3%	3.42 [0.14, 83.60]	
2014 Weston (DAP)	79	100	43	50	13.4%	0.61 [0.24, 1.56]		2014 Weston (DAP)	49	100	33	50	12.1%	0.49 [0.24, 1.00]	
2015 Usery (DAP/LNZ)	45	50	58	61	5.8%	0.47 [0.11, 2.05]		2015 Usery (DAP/LNZ)	33	54	40	68	7.4%	1.10 [0.53, 2.28]	
2016 Moise (DAP)	50	69	61	77	17.6%	0.69 [0.32, 1.48]		2016 Claeys (DAP)	72	131	93	131	22.6%	0.50 [0.30, 0.83]	
2018 Kalimuddin (DAP)	7	7	7	7		Not estimable		2016 Moise (DAP)	65	85	76	85	9.6%	0.38 [0.16, 0.90]	
2021 Barlow (DAP/CPT)	37	43	13	13	3.4%	0.21 [0.01, 4.05]		2018 Pericas (FOS+IPM)	1	3	3	4	0.9%	0.17 [0.01, 4.51]	
 A state of the sta															
Total (95% CI)		585		442	100.0%	0.58 [0.41, 0.82]	▼	Total (95% CI)		691		854	100.0%	0.53 [0.42, 0.68]	•
Total events	460		375				a a a a	Total events	410		623			L	
Heterogeneity: Chi ² = 8.96, d			²=0%				0.001 0.1 1 10 1000	Heterogeneity: Chi ² = 14.38,	df = 14 (P :	= 0.42);	≥ =3%				
Test for overall effect: Z = 3.1	2 (P = 0.00	02)					Favours [Comparators] Favours [Vancomycin]	Test for overall effect: Z = 5.1	5 (P < 0.00	0001)					Favours [Comparators] Favours [Vancomycin]

The subgroup analysis of TEC and LNZ showed no differences. The difference was concentrated in the subgroup of DAP (888 cases, **OR=0.55, 95%CI 0.38-0.80, p=0.002**), in which VAN had a significantly lower microbiological eradication rate.


The subgroup analysis of TEC and LNZ showed no differences. The difference was concentrated in the subgroup of DAP (1036 cases, **OR=0.48, 95%CI 0.36-0.63, p<0.00001**), in which VAN had a significantly lower clinical cure rate.

Targeted therapy of severe infections caused by *S. aureus* in critically ill adult patients



Green box: best therapeutic regimen according to current evidence; yellow box: alternative therapeutic regimen according to current evidence; red box: therapeutic regimen recommended only in specific situations.


Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible *S. aureus* during therapy improves antibacterial activity



Clinical data on daptomycin plus ceftaroline versus standard of care monotherapy in the treatment of MRSA bacteremia

Pilot study, 40 adult patients who were randomized to receive 6-8 mg/kg of body weight per day of DAP and 600 mg CPT every 8 h (q8h) (n=17) or standard monotherapy (n=23) with vancomycin (VAN; dosed to achieve serum trough concentrations of 15 to 20 mg/liter; n=21) or 6-8 mg/kg/day DAP (n=2) were evaluated.

The findings led the investigators to stop early the study due to an unacceptable higher risk of mortality in the monotherapy arm (0% [0/17] for combination therapy and 26% [6/23] for monotherapy). Survival analysis of patients receiving DAP/CPT compared with those receiving SOC




Vancomycin or daptomycin plus a β-Lactam versus vancomycin or daptomycin alone for MRSA bloodstream infections: a meta-Analysis

Literature search identified 3 randomized clinical trials and 10 observational studies involving at least 1796 patients

in-hospital mortality	risk of 30-day mortality	risk of 60-90-day mortality
RR 0.59	RR 1.10	RR 0.91
95%CI 0.31-1.13	95%CI 0.82-1.46	95%CI 0.64-1.29
shorter duration of bacteremia	risk of persistent bacteremia	risk of bacteremia 60-90-day recurrence
shorter duration of bacteremia mean difference -1.06 days	risk of persistent bacteremia RR 0.63	risk of bacteremia 60-90-day recurrence RR 0.61

In subgroup analysis, when the analysis was limited to the studies comparing using DAP plus ceftaroline with monotherapy, the former had a lower risk of mortality within 30 days. In addition, a subgroup analysis limited to RCTs showed that the combination therapy was associated with a higher risk of AKI compared with using VAN or DAP alone.


Synergy mechanisms of daptomycin-fosfomycin combinations in daptomycin-susceptible and -resistant MRSA



Mishra NN, Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0164921.

Daptomycin plus fosfomycin vs daptomycin alone for MRSA bacteremia and endocarditis: a randomized clinical trial (BACSARM study)

A randomized phase 3 superiority, open-label, and parallel group clinical trial of adult inpatients with MRSA bacteremia was conducted in Spain (18 hospitals). Patients were randomly assigned to receive either daptomycin plus fosfomycin, or daptomycin alone. Primary endpoint was treatment success 6 weeks after the end of therapy.



Road map


- Time-to-antibiotics and clinical outcomes
- Initial treatment for MRSA infections

• Role of piperacillin/tazobactam in CRO-R *E. coli* infections


- Carbapenemase-producing *Enterobacterales* BSI in rectal carriers
- Impact on clinical outcome of follow-up blood cultures
- Early oral switch in bloodstream infections

Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for E. coli or K. pneumoniae BSI and CRO-R (MERINO)

Noninferiority, RCT included hospitalized patients enrolled from 26 sites in 9 countries (2014 to 2017) to determine whether definitive therapy with TZP is noninferior to meropenem in patients with BSI caused by CRO-R *E. coli* or *K. pneumoniae*. The primary outcome was all-cause mortality at 30 days after randomization.



Association between MIC and mortality for patients treated with piperacillin/tazobactam or meropenem from the MERINO study




TZP nonsusceptible breakpoint (MIC >16 mg/L) best predicted 30-day mortality after accounting for confounders (OR 14.9, 95%CI 2.8-87.2).

Absolute risk increase for 30-day mortality for patients treated with TZP compared with meropenem reduced to 5% (95%CI -1% to 10%) after excluding strains with TZP MIC values >16 mg/L.

Association of piperacillin/tazobactam MIC and mortality in a cohort of CRO-R *E. coli* BSIs treated with TZP and carbapenems

A multicentre retrospective cohort study was conducted in 3 hospitals in Italy between 2018 and 2022. The study population comprised patients with monomicrobial 3GC-R *E. coli* BSI, who received either empirical Tx with TZP or carbapenem therapy within 48h of blood culture collection. The primary outcome was in-hospital 30-day all-cause mortality. Of the 412 consecutive patients, 51% received TZP, while 49% received carbapenems.




Association of piperacillin/tazobactam MIC and mortality in a cohort of CRO-R *E. coli* BSIs treated with TZP and carbapenems

A multicentre retrospective cohort study was conducted in 3 hospitals in Italy between 2018 and 2022. The study population comprised patients with monomicrobial 3GC-R *E. coli* BSI, who received either empirical Tx with TZP or carbapenem therapy within 48h of blood culture collection. The primary outcome was in-hospital 30-day all-cause mortality. Of the 412 consecutive patients, 51% received TZP, while 49% received carbapenems.

	Crue	de model	Propen	sity-adjusted
Characteristic	HR	95% CI	HR	95% CI
Empirical TZP	1.34	0.78-2.32	1.38	0.85-2.16
Immunocompromised	0.88	0.47-1.66	0.79	0.43-1.41
CCI	1.07	0.96-1.19	1.08	0.98-1.17
Pitt bacteraemia score	1.23	1.10-1.38	1.26	1.13-1.40
TZP MIC (mg/L)				
8	2.29	1.25-4.21	2.35	1.35-3.95
≥16	3.04	1.49–6.19	3.69	1.86-6.91

Multiple Cox regression models for in-hospital 30-day mortality

In vitro killing of parenteral beta-lactams against standard and high inocula of ESBL producing K. pneumoniae




Burgess DS, Diagn Microbiol Infect Dis. 2004 May;49(1):41-6.

Road map


- Time-to-antibiotics and clinical outcomes
- Initial treatment for MRSA infections
- Role of piperacillin/tazobactam in CRO-R *E. coli* infections
- Carbapenemase-producing *Enterobacterales* BSI in rectal carriers
- Impact on clinical outcome of follow-up blood cultures
- Early oral switch in bloodstream infections

Risk factors for infections caused by CRE: EURECA study




Progression from carriage of various carbapenemases to BSI

A nationwide population-based retrospective cohort study using national databases was conducted. The cohort consisted of all patients in Israel with CPE detected by screening from 1/1/2020 to 10/10/2022. The study included 6828 CPE carriers.



Progression from carriage of various carbapenemases to BSI

A nationwide population-based retrospective cohort study using national databases was conducted. The cohort consisted of all patients in Israel with CPE detected by screening from 1/1/2020 to 10/10/2022. The study included 6828 CPE carriers.




More than 1: more than 1 carbapenemase; Tertiary/nontertiary refers to acute care hospital type; PACH: post-acute care hospital; KPC, Klebsiella pneumoniae carbapenemase; NDM, New Delhi metallo-β-lactamase

Time-to-onset of carbapenemase-producing *Enterobacterales* infections in CPE carriers

A retrospective cohort study was performed over a 10-year period in a University Hospital in France.

All infectious episodes within the first 6 months following the diagnosis of CPE rectal carriage were considered




93 infectious episodeswere identified in the first6 months following itsdiagnosis.

CPE infection occurred earlier than any other infections (P < 0.01), with a median of 15 days (Q1 to Q3 = 8 to 24) compared with 51 days (Q1 to Q3 = 25 to 109)


Hoellinger B, Microbiol Spectr. 2022 Dec 21;10(6):e0186822.

Proportion of carbapenemase-producing *Enterobacterales*-colonised patients developing bacteraemia caused by non-CPE vs. CPE



Risk factors for carbapenem-resistant *K. pneumoniae* bloodstream infection among rectal carriers

KM analysis of CR-KP of BSI probability at five risk score levels



KM analysis of CR-KP of BSI probability at five risk score levels

ICU	OR 1.65; p = 0.03	2 points
abdominal invasive procedure	OR 1.87; p = 0.01	3 points
chemotherapy/radiation therapy	OR 3.07; p<0.0001	4 points
number of additional colonization sites	OR 3.37 per site; p<0.0001	5 points per site

Giannella M, Clin Microbiol Infect. 2014 Dec;20(12):1357-62.


Antimicrobial activity spectrum chart

	ESBL Pro- ducer	Amp C Pro- ducer	KPC-Type Producer	NDM- Type Producer	OXA-48- like Producer	Carbapenem- Resistant <i>P.</i> aeruginosa	Carbapenem- Resistant A. baumannii	S. mal- tophilia
Colistin/polymixyn								
Fosfomycin								
Tigecycline								
Ceftazidime/avibactam								
Ceftolozane/tazobactam								
Imipenem/relebactam								
Meropenem/vaborbactam								
Cefepime/taniborbactam								
Cefepime/enmetazobactam								
Cefepime/zidebactam								
Aztreonam/avibactam								
Cefiderocol								
Eravacycline								
Plazomicin								
Temocilin								
Ampiciline-sulbactam								

Road map

- Time-to-antibiotics and clinical outcomes
- Initial treatment for MRSA infections
- Role of piperacillin/tazobactam in CRO-R *E. coli* infections
- Carbapenemase-producing *Enterobacterales* BSI in rectal carriers
- Impact on clinical outcome of follow-up blood cultures
- Early oral switch in bloodstream infections


Positive follow-up blood cultures identify high mortality risk among patients with Gram-negative bacteraemia



Propensity score-weighted Cox model revealed that: -obtaining FUBCs was associated with reductions in all-cause mortality (**HR 0.63; 95%CI 0.51-0.77**)

-positive FUBCs were associated with increased allcause mortality (**HR 2.10; 95%Cl 1.57-2.81**)

attributable mortality




Propensity score-weighted Cox model revealed that: -obtaining FUBCs was associated with reduction in attributable mortality (**HR 0.63; 95%CI 0.48-0.82**)

-positive FUBCs were associated with increased attributable mortality (**HR 1.80; 95%CI 1.24-2.60**)

Impact on clinical outcome of follow-up blood cultures and risk factors for persistent bacteraemia in patients with gram-negative bloodstream infections: a systematic review with meta-analysis

A Meta-analysis was performed. A total of 3747 articles were screened, and 11 observational studies (6 assessing impact on outcome (N = 4631), and 5 investigating risk factors for persistent GN-BSI (N = 2566), conducted between 2002 and 2020 were included.




Impact on clinical outcome of follow-up blood cultures and risk factors for persistent bacteraemia in patients with gram-negative bloodstream infections: a systematic review with meta-analysis

A Meta-analysis was performed. A total of 3747 articles were screened, and 11 observational studies (6 assessing impact on outcome (N = 4631), and 5 investigating risk factors for persistent GN-BSI (N = 2566)), conducted between 2002 and 2020 were included.

Independent risk factors for persistent bacteraemia

end-stage renal disease	OR 2.99; 95%CI_1.77-5.05
central venous catheter	OR 3.30; 95%CI 1.82-5.95
infections due to ESβL-producing strains	OR 2.25; 95%CI 1.18-4.28
resistance to empirical treatment	OR 2.70; 95%CI 1.65-4.41
unfavourable response at 48 hours	OR 2.99; 95%CI 1.44-6.24

Follow-up blood culture in Gram-negative bacilli bacteraemia: for whom is follow-up blood culture useful?



Road map

- Time-to-antibiotics and clinical outcomes
- Initial treatment for MRSA infections
- Role of piperacillin/tazobactam in CRO-R *E. coli* infections
- Carbapenemase-producing *Enterobacterales* BSI in rectal carriers
- Impact on clinical outcome of follow-up blood cultures
- Early oral switch in bloodstream infections

Efficacy and safety of an early oral switch in low-risk *S. aureus* bloodstream infection (SABATO): an international, open-label, parallel-group, randomised, controlled, non-inferiority trial


An international RCT done in 31 tertiary care hospitals in Europe, patients with low-risk *S. aureus* BSI were randomly assigned after 5-7 days of IV therapy to oral therapy or to continue IV therapy.

Adult patients with *S aureus* isolated from at least 1 blood culture were eligible if they had received 5-7 days of appropriate IV therapy, initiated within 72 h after the first positive blood culture was drawn, and at least 1 follow-up blood culture obtained within 24-96h after the start of appropriate therapy. Blood cultures taken in this period had to be negative for *S aureus* for the patient to be included.

Oral antimicrobials were selected by the study physician (according to susceptibility and suspected allergy or intolerance): co-trimoxazole for MSSA and MRSA, clindamycin for MSSA or linezolid for MRSA in the oral switch group; and IV flucloxacillin or cloxacillin, cefazolin, or vancomycin for MSSA or vancomycin or daptomycin for MRSA in the IV group.

The clinically evaluable population consisted of 165 participants, with 86 participants in the oral switch group and 79 participants in the intravenous standard therapy group.

Efficacy and safety of an early oral switch in low-risk *S. aureus* bloodstream infection (SABATO): an international, open-label, parallel-group, randomised, controlled, non-inferiority trial



Efficacy and safety of an early oral switch in low-risk *S. aureus* bloodstream infection (SABATO): an international, open-label, parallel-group, randomised, controlled, non-inferiority trial


	Intention-to-trea	at population		Clinically evalu	Clinically evaluable population			
	Oral switch group (n=108)	Intravenous group (n=105)	Percentage-point difference (95% Cl)	Oral switch group (n=86)	Intravenous group (n=79)	Percentage-point difference (95% CI)		
Primary endpoint								
SAB-related complication within 90 days	14 (13%)	13 (12%)	0.7 (-7.8 to 9.1)	3 (4%)	4 (5%)	-2·9 (-9·6 to 3·9)		
Reason primary outcome was met								
SAB-related complication	6 (6%)	8 (8%)	-2·1 (-9·7 to 5·5)	3 (4%)	4 (5%)	-1.6 (-9.0 to 5.8)		
Relapsing SAB	3 (3%)	4 (4%)	-1·0 (-6·8 to 4·7)	2 (2%)	2 (3%)	-0·2 (-5·1 to 4·7)		
Deep-seated infection with <i>S aureus</i>	5 (5%)	8 (8%)	-3·0 (-10·4 to 4·4)	3 (4%)	4 (5%)	-1.6 (-9.0 to 5.8)		
Death attributable to SAB	2 (2%)	0	1·9 (-1·6 to 5·3)	1 (1%)	0	1·2 (-2·3 to 4·6)		

Early switch from intravenous to oral antibiotics for patients with uncomplicated Gram-Negative bacteremia


Cohort study conducted in adults with uncomplicated GNB bacteremia in 4 hospitals in Denmark. The duration of followup was 90 days. Eligibility criteria included a blood culture positive for growth of GNB, clinical stability within 4 days of initial blood culture, an available susceptibility report on day 4, and initiation of appropriate IV antibiotic Tx within 24 hours of blood culture. Of 914 eligible individuals, 433 (47.4%) switched early to oral antibiotics while 481 (52.6%) received prolonged IV antibiotics (minimum of 5 days).

No. at risk

IPW 90-day risk of all-cause mortality among individuals continuing IV therapy vs early switch to oral antibiotic



Survival curves for individuals who continued or switched to early oral antibiotics



Tingsgård S, .JAMA Netw Open. 2024 Jan 2;7(1):e2352314.

Ongoing RCTs on early oral stepdown

INVEST trial

Early oral stepdown antibiotic therapy for uncomplicated Gram-negative bacteraemia -NCT05199324. **SOAB** trial

Switch to Oral Antibiotics in Gram-Negative Bacteremia - NCT04146922.

Recruiting

INVEST trial randomizes patients to either early oral stepdown within 3 days or continuation of IV antibiotic therapy for at least 24 hours after randomization before clinical reassessment.

Completed

SOAB trial randomized patients to either early oral stepdown between days 3 to 5 or continuation of IV treatment for the entire treatment duration.

In both trials, clinical stability, defined as being afebrile and hemodynamically stable, was required for eligibility.